Soleno Therapeutics (NASDAQ:SLNO) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a buy rating to a hold rating in a research report sent to investors on Sunday.

Several other research firms have also issued reports on SLNO. HC Wainwright dropped their price target on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Wells Fargo & Company decreased their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. TD Cowen dropped their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $104.54.

Soleno Therapeutics Stock Down 1.2%

SLNO stock opened at $31.34 on Friday. The company has a market cap of $1.62 billion, a price-to-earnings ratio of 136.27 and a beta of -3.16. Soleno Therapeutics has a twelve month low of $30.11 and a twelve month high of $90.32. The business has a 50 day moving average price of $39.18 and a two-hundred day moving average price of $49.19. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. Analysts anticipate that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics during the 2nd quarter worth about $25,000. Avanza Fonder AB grew its stake in Soleno Therapeutics by 11.2% in the 4th quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock valued at $148,000 after buying an additional 323 shares during the last quarter. Principal Financial Group Inc. grew its stake in Soleno Therapeutics by 11.9% in the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after buying an additional 340 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Soleno Therapeutics by 2.4% in the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares during the period. 97.42% of the stock is owned by institutional investors.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Short‑interest reports posted today are internally inconsistent (showing 0 shares and “NaN” changes across multiple feed updates). The data appears erroneous and is unlikely to explain the stock move.
• Neutral Sentiment: Soleno’s price movement also tracked a broader Nasdaq decline, suggesting part of the drop is market‑wide pressure rather than company‑specific news. Soleno Therapeutics (NASDAQ:SLNO) Moves With Broader Nasdaq Index Decline
• Negative Sentiment: A formal securities class action has been filed alleging Soleno made material misstatements/omissions about its Phase 3 DCCR program and related launch/safety issues — this is the primary negative catalyst driving investor concern. Such cases can produce settlements, legal costs, and reputational damage. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Pomerantz, Schall, Rosen, Bernstein, Faruqi, Robbins, Bronstein, etc.) have issued investor alerts soliciting lead‑plaintiff actions and filing notices, amplifying the legal overhang and press coverage that can pressure the stock. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
• Negative Sentiment: Investor‑facing headlines explicitly cite alleged concealment of commercial and safety risks tied to DCCR — if allegations gain regulatory or evidentiary traction, downside risk increases beyond short‑term trading volatility. SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.